Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01003860 · ClinicalTrials.gov registry record
Postoperative Analgesia After Shoulder Replacement
A clinical trial, sponsored by Thomas Jefferson University.
- Completed
- Registry status
- 39
- Enrollment target
NCT01003860: Completed study, sponsored by Thomas Jefferson University.
NCT01003860 is a clinical trial that has completed, run by Thomas Jefferson University. The registered enrollment target is 39 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01003860 has completed, sponsored by Thomas Jefferson University.
- COMPLETED
- Registry status
- 39 participants
- Enrollment target
Study Summary
A comparison was made regarding opioid analgesic usage immediately after elective shoulder replacement and for seven days at home between patients randomly given either 0.5% or 0.75% ropivacaine via interscalene block prior to surgery. It is hypothesized that no significant difference will exist between both groups with respect to pain medication used in the hospital and for a 7-day period at home.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2006-06 |
| Est. Completion | 2007-04 |
What the finished NCT01003860 record still lists
NCT01003860 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 39 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01003860 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01003860 about?
NCT01003860 is a clinical study titled "Postoperative Analgesia After Shoulder Replacement". A comparison was made regarding opioid analgesic usage immediately after elective shoulder replacement and for seven days at home between patients randomly given either 0.5% or 0.75% ropivacaine via interscalene block prior to surgery. It is hypothesized that no significant difference will exist be...
What is the current status of trial NCT01003860?
This trial is currently completed. The enrollment target is 39 participants. The study started on 2006-06. Estimated completion is 2007-04.
Who is sponsoring clinical trial NCT01003860?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia